(Q67955737)
Statements
Use of recombinant IL-2 (RU49637) after autologous bone marrow transplantation (BMT) in patients with hematological neoplasias: a phase 1 study (English)
Blaise D
Stoppa AM
Olive D
Brandely M
Tiberghien P
Attal M
Attal J
Reiffers J
Demeocq F
1 January 1991